New preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at ESC Congress 2024
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced new preclinical data indicating that drug candidate CS585, a novel prostacyclin (IP) receptor agonist, inhibits platelet activation and clot formation up to 24 hours post-administration. The new data was presented at the ESC (European Society of Cardiology) Congress 2024, on August 30–September 2, 2024.CS585, was shown to inhibit platelet activation and clot formation in the blood up to 24 hours post administration. In both in vivo